{
  "docId": "019de071-393b-7632-a337-54e7c94a82e1",
  "docSlug": "0665efd8ee492718ecd4a60e3f8fd33f",
  "documentTitle": "argenx SE | Results Presentation Deck | 16 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 16,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a process-like flow to connect disease categories to specific autoantibody findings and clinical trial/regulatory status.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de071-393b-7632-a337-54e7c94a82e1/6",
  "deckHref": "/decks/019de071-393b-7632-a337-54e7c94a82e1",
  "deckJsonHref": "/decks/019de071-393b-7632-a337-54e7c94a82e1.json",
  "deckAnchorHref": "/decks/019de071-393b-7632-a337-54e7c94a82e1#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "callout",
      "text": "IND filing by end of 2021 pending interactions with FDA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f724491-3ff2-4086-a2c8-bfd287fea4f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.03,
        "y": 0.285
      },
      "kind": "list",
      "text": "Neuromuscular Disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc2122d2-b18d-47d0-bb9d-df403c60fcbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.23,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Myasthenia Gravis; Chronic Inflammatory Demyelinating Polyneuropathy; Myositis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "009acb18-ac4a-47d9-9f1a-8c983581a702",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "AChR, MuSK, LRP4 autoantibodies comprise ~90% of MG patients; 40% anti-myelinated peripheral nerve IgGs; Autoantibodies characterized in 70% of patients across IMNM, ASyS and DM",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1cb60a1-1814-4d7c-947e-b4269fbbc3da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.15,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "IMNM: Immune-Mediated Necrotizing Myopathy ASyS: Anti-Synthetase Syndrome DM: Dermatomyositis. Gilhus et al., Nature Rev/Disease Primers. 2019; Gilhus et al., NEJM, 2016; Querol et al., Nat Rev Neurol. 2017; Schmidt, Journal Neuromusc Diseases. 2018; Aquilar-Vazquez et al., Frontiers in Immunology. 2021; McHugh, Managing Myositis. 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "551571c9-5d4d-4c15-88bb-d6230e96f01b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Myositis: IgG-Mediated Biology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc672880-6b41-4538-b78c-712b9043efc4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "852ae9ca-281a-42a5-9f45-70ab7c58c410",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a solution on slide 5 and develops it on slides 6-8",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0e64f6d5-bcb4-4f93-8d22-81ecae10d41d",
      "evidence": "The document presents a 'why' on slide 3 and develops it on slides 4-10",
      "position": 0,
      "objective": "Why Efgartigimod?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 9,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2545deac-471a-48e0-95d8-493878652df8",
      "evidence": "The document presents a cost of inaction on slides 6-9",
      "position": 1,
      "objective": "What happens if we don't act?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}